Improving diagnosis and care for AL amyloidosis and related conditions
Part of Blood & lymphatic, Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed and have not received any treatment for your condition yet.
- You need to be 18 years or older.
- You must be able to understand and sign a consent form.
- For Part A: You have MGUS with an abnormal free light chain ratio, or smoldering multiple myeloma.
- For Part B: You have systemic AL amyloidosis (not caused by other types of amyloid or other diseases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is screening people with smoldering multiple myeloma or a monoclonal gammopathy to see if they might have an early form of AL amyloidosis, a condition where abnormal proteins build up in organs. If you meet the criteria, you will be tested to find out if you have amyloidosis, which could help catch it early.
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
This trial uses special imaging scans to detect amyloidosis (abnormal protein buildup) early in people who have monoclonal gammopathy (an abnormal blood protein). The goal is to find amyloidosis before it causes serious organ damage.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.